Does DCTH pay a dividend and is it safe?

Delcath Systems Inc. (DCTH) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / DCTH / dividends

RCEL (46) SENS (40) SSII (30) ANGO (36) ⌘ Pro Terminal →

Delcath Systems Inc. (DCTH) Dividend Safety Gauge & 10-Year DRIP Compounder

$14.29 +1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.31

Delcath Systems Inc. (DCTH) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $487.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DCTH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DCTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Delcath Systems Inc. (NASDAQ: DCTH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $14.29 (+1.78% 1D, market cap $487.2M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, DCTH ranks #172 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DCTH compare to RCEL and SENS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), DCTH carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 86.2%, and ROIC of 0.8%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $484.0M) and SENS (Senseonics Holdings Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M). Among the 5-stock peer group, DCTH leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DCTH?

▼

Per DCTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000872912), Delcath Systems Inc. generated $85.2M in revenue (+129.1% YoY), $2.7M in net income, and $21.0M in free cash flow against $123.6M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.31 (+0.13%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 24.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DCTH)Realized 20D OHLCV Swing Band: ±7.7%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY DCTH SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (31% of score)

Altman Z-Score 20.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 24.6% FCF Margin ($21.0M FCF) & 86.2% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$15.32-3.7% Next Q

Q2 (-2Q)

Grade C+$14.76-0.1% Next Q

Q3 (-1Q)

Grade C+$14.75-3.1% Next Q

Current

Grade C-$14.29+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DCTH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, DCTH faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 83.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.56) or 200D SMA ($12.38) invalidates the momentum regime and cuts Target Base ($14.35) toward Bear Floor ($11.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DCTH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DCTH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in DCTH & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on DCTH and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DCTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.67%🛡️ HOLDING TREND SUPPORT

2026-11-03O $14.64H $14.64L $14.04C $14.29VOL 427.4K

RES: $15.16SUP: $13.98SMA50: $15.56SMA200: $12.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DCTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DCTH Butterfly Map → + Track DCTH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +129.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DCTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DCTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DCTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DCTH)

Health Care Rank #172 of 1016 ⚔️ RCEL vs DCTH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DCTH vs. RCEL, SENS, SSII, ANGO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Delcath Systems Inc. (DCTH) ranks #172 by composite RQD confidence (59/100, grade C-) and #448 by equity capitalization ($487.2M). Within this direct 5-issuer industry benchmark cohort, DCTH leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DCTH ACTIVE Delcath Systems Inc.	C-	59/100	—	86.2%	0.8%	+1.78%	$487.2M	Benchmark Subject
RCEL Avita Medical Inc.	D	46/100	—	82.1%	-35.0%	-1.53%	$484.0M	/rcel-vs-dcth →
SENS Senseonics Holdings Inc.	D-	40/100	—	44.7%	-35.0%	-5.57%	$502.8M	/sens-vs-dcth →
SSII SS Innovations International Inc.	E	30/100	—	46.0%	-18.5%	-1.70%	$471.1M	/ssii-vs-dcth →
ANGO AngioDynamics Inc.	D-	36/100	—	54.6%	-23.4%	-1.92%	$504.2M	/ango-vs-dcth →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000872912

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Delcath Systems Inc. (DCTH) reported GAAP revenue of $85.2M (+129.1% vs. FY2024 revenue of $37.2M , and +4027.4% cumulative change since FY2023) , GAAP net income of $2.7M, operating cash flow of $22.5M, and free cash flow of $21.0M (+209.0% YoY). On the balance sheet, DCTH closed FY2025 with $123.6M in total assets against $0 in total debt (Altman Z-Score: 20.33, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$85.2M	$2.7M	$22.5M	$21.0M	$123.6M	—
FY2024 (FY)	2024-12-31	$37.2M	-$26.4M	-$18.7M	-$19.2M	$76.6M	—
FY2023 (FY)	2023-12-31	$2.1M	-$47.7M	-$31.3M	-$31.3M	—	—

3. DCTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DCTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DCTH compare to RCEL and SENS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DCTH?

Where is DCTH trading relative to its 50-day, 200-day, and 52-week technical levels?

DCTH last traded at $14.29 (+1.78% on volume of 364,906 shares), positioning the stock -8.16% below its 50-day simple moving average ($15.56) and +15.43% above its 200-day simple moving average ($12.38). Across its 52-week range of $8.12 to $17.42, DCTH sits at the 66.3% percentile with a 14-day RSI of 40.0 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($13.19 to $15.39).

Direct Sub-Reports: DCTH RQD Cockpit DCTH 12M Forecast DCTH Earnings & Move DCTH Dividends & DRIP DCTH Insiders & 13F DCTH Whale Options DCTH Profit Sankey DCTH News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

DCTH — Delcath Systems Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Delcath Systems Inc. (DCTH) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $14.29 (+1.78% 1D, market capitalization $487.2M).

Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 0.8%, gross margin of 86.2%, operating margin of 0.8%, and free cash flow yield of 4.13%.
Whale 13F & Options Flow (7/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 20.33, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Delcath Systems Inc. (DCTH) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. The profile identifies the company as operating in this sector and industry with a market capitalization of $0.5B. Reported revenue grew from $2.1M in FY 2023 to $37.2M in FY 2024 and $85.2M in FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Delcath Systems Inc. (DCTH) reported $85.2M in annual revenue (up from $37.2M in FY2024, +129.1% YoY) and $2.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.1M revenue, -$47.7M net income) through FY2025, DCTH scaled operating cash flow to $22.5M and free cash flow to $21.0M, backed by $123.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C- • RQD 59/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 4.13% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $8.12 – $17.42 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against 0.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream links and no sector correlations. Investors should note that the dossier therefore cannot map supplier, customer, or competitor dependencies from the provided sources.

Key Question #1: Can DCTH sustain or expand its 0.8% operating margin and 0.8% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $85.2M and free cash flow of $21.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is DCTH's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DCTH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Delcath Systems Inc. (DCTH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DCTH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

Delcath Systems to Host Third Quarter 2026 Earnings Call

Yahoo Finance report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 23h ago

Delcath Systems Q2 2026 Earnings Call Transcript

Benzinga report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 1d ago

These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months

Stocktwits report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A live webcast of the UBS conference will be available on Delcath's investor site, with an archive too.

Stock Titan report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 1d ago

How (DCTH) Movements Inform Risk Allocation Models

Stock Traders Daily report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Delcath Systems (DCTH) Slips 2.24% to $14.42 as Shares Drift Toward Lower Support - Bollinger Walk

https://www.siam.in/ report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

BlackRock reports a passive stake above 5% in Delcath Systems (DCTH).

Stock Titan report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(DCTH) Volatility Zones as Tactical Triggers

Stock Traders Daily report covering Delcath Systems Inc. (DCTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DCTH Bull vs. Bear Conversation Board — What's Your Call at $14.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DCTH 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $17.41 (+24.0%)

📌 Pinned Debate

Revenue scaled from $2.1M in FY 2023 to $85.2M in FY 2025 with FY 2025 FCF of $21.0M, and the forensic balance sheet scores 18 of 20.

Here is why I am bullish on DCTH here at $14.04: Revenue scaled from $2.1M in FY 2023 to $85.2M in FY 2025 with FY 2025 FCF of $21.0M, and the forensic balance sheet scores 18 of 20.. Compare DCTH's 0.8% operating margin and 0.8% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $13.34 are getting bought.

CapAlloc_Nerd 🐂 BULL

@QuantViper Agree on the RQD 59/100 quality, though with 1.0 beta I'm scaling in with half-size at $14.04 and keeping dry powder in case we test $13.06.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $10.67 (-24.0%)

Spot @ $14.04

ROIC is only 0.8% and operating margin is 0.8%, with macro regime fit scoring 9 of 20 and no earnings multiples available to justify va

ROIC is only 0.8% and operating margin is 0.8%, with macro regime fit scoring 9 of 20 and no earnings multiples available to justify valuation.. Look at the math on DCTH: paying current EV/EBITDA multiples for 0.8% ROIC and 0.8% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $12.36 before getting long.